CStone Pharmaceuticals (HKG:2616) intends to buy back up to nearly 136.5 million shares from the open market from time to time under a mandate approved June 25, 2025, according to a Wednesday Hong Kong bourse filing.
The repurchase plan is expected to be implemented following the American Society of Clinical Oncology (ASCO) Annual Meeting.